浏览全部资源
扫码关注微信
国家知识产权局专利局 专利审查协作四川中心,成都 610213
Published:20 February 2023,
Published Online:01 December 2022,
Received:15 July 2022,
扫 描 看 全 文
黄大智,陈昊.中日两国中药经典名方专利申请主体的申请策略比较[J].中国实验方剂学杂志,2023,29(04):192-201.
HUANG Dazhi,CHEN Hao.Comparison of Application Strategies of Patent Applicants of Classic Traditional Chinese Medicine Prescriptions Between China and Japan[J].Chinese Journal of Experimental Traditional Medical Formulae,2023,29(04):192-201.
黄大智,陈昊.中日两国中药经典名方专利申请主体的申请策略比较[J].中国实验方剂学杂志,2023,29(04):192-201. DOI: 10.13422/j.cnki.syfjx.20230113.
HUANG Dazhi,CHEN Hao.Comparison of Application Strategies of Patent Applicants of Classic Traditional Chinese Medicine Prescriptions Between China and Japan[J].Chinese Journal of Experimental Traditional Medical Formulae,2023,29(04):192-201. DOI: 10.13422/j.cnki.syfjx.20230113.
该文以《伤寒杂病论》和《金匮要略》中的290个方剂及《方剂学》中的191个正方作为中药经典名方的代表,制作方剂中日文翻译表,以方剂名称为关键词并进行相关拓展,检索截至2022年6月的专利申请数据,检索结果通过数据清洗和人工降噪,以重点申请主体为切入点,根据中药经典名方技术改进特点进行关键技术的划分和标引,深度挖掘两国中药经典名方专利申请的情报信息,并进一步比较我国与日本申请主体在中药经典名方专利申请及布局策略上的差异。该文拟定了准确并具有针对性的检索策略,对中日两国具有代表性的专利申请主体的经典名方专利数据进行了更准确和全面的检索、梳理、统计,同时深度挖掘日本本国汉方专利申请的情报信息,以中日两国具有代表性的申请主体的中药经典名方专利布局作为切入点,针对我国中药经典名方与日本汉方在专利申请策略和专利保护方面的差异进行了比较。一方面有助于准确把握目前两国中药经典名方的专利申请状况,另一方面也可为国内企业、高校和研究机构的经典名方二次开发研究及专利申请和布局提供一定的参考。
A total of 290 prescriptions in
Treatise on Typhoid and Miscellaneous Diseases
(《伤寒杂病论》) and
Synopsis of the Golden Chamber
(《金匮要略》) and 191 prescriptions in
Prescriptionology
were selected as representatives of classical prescriptions of traditional Chinese medicine (TCM), which were translated into Chinese and Japanese. The prescription names were used as keywords for search, and the patent application data up to June 2022 were retrieved. The retrieved results underwent data cleaning and manual noise reduction. Taking the important applicants as the starting point, the key technologies were divided and indexed according to the technical improvement characteristics of classic TCM prescriptions, and the intelligence information of patent applications for classic TCM prescriptions in the two countries was deeply excavated. The differences in the patent applications and layout strategies of classic TCM prescriptions between China and Japan were further compared. This paper drew up an accurate and targeted search strategy for more accurate and comprehensive retrieval, collation, and statistics of patent data of classic TCM prescriptions of representative patent applicants in China and Japan. At the same time, this paper deeply explored the information on Chinese patent applications in Japan and compared the differences in patent application strategies and patent protection of classic TCM prescriptions and Chinese prescriptions in Japan taking the layout of classic TCM prescriptions of representative patent applicants in China and Japan as the entry point. On one hand, it can accurately grasp the current patent application status of classic TCM prescriptions in the two countries, and on the other hand, it can also provide some references for the secondary development and research, patent application, and layout of classic prescriptions of enterprises, universities, and research institutions in China.
中药经典名方专利分析中国日本申请策略
classical prescriptions of traditional Chinese medicinepatent analysisChinaJapanapplication strategies
郑绳一.从专利情况观察日本汉方药的趋向[J].中成药研究,1983(10):46-47.
陈朝晖,黄春春,何岚.日本中医药专利分析及中日专利体系的比较[J].中草药,2006(2):298-300.
翁丽红,林丹红.传统医药企业知识产权战略分析——以日本津村株式会社为例[J].福建中医药大学学报,2013,23(4):66-69.
李振飞,翟东升,冯秀珍,等.中药企业国际化知识产权协同分析——以津村株式会社和北京同仁堂为例[J].情报杂志,2015,34(7):105-109,94.
薛姣,李黎,齐洁.日本企业围绕小柴胡复方的专利布局研究[J].广东化工,2017,44(16):162-163.
宋傲男,张东婷,刘佩佩,等.专利视角下的中药国际影响力研究[J].中草药,2017,48(15):3245-3252.
郭德海.跨国医药公司在华专利战略分析及对中药产业的启示研究[D].北京:中国中医科学院,2008.
王言.中药复方二次开发的可专利性研究[J].时珍国医国药,2008(5):1191-1193.
张芙婧,谌侃.中日两国中药PCT专利申请比较研究[J].中国医药生物技术,2017,12(1):88-91,93.
程诚,尹婷.基于专利布局分析的中药复方创新趋势研究[J].中国发明与专利,2017,14(10):28-35.
陈彬彬,陈瑶.中国中药与日本汉方药发展状况比较[J].中西医结合心血管病电子杂志,2017,5(35):7-9.
于佳佳.传统医疗在日本的复兴和发展——以“标准”和“规范”为着眼点[J].复旦国际关系评论,2018(2):39-55.
王诗恒,刘剑锋,秦培洁,等.日本汉方药产业管理现状概况[J].世界中医药,2021,16(2):351-354.
高红艳,宋欣阳,黄奕然,等.中药国际标准构建的战略思考[J].世界科学技术—中医药现代化,2021,23(1):33-38.
刘岳琪,宿军慧,曹君杰,等.日本汉方药企业近十年申请专利的分析及思考——以津村制药和Kracie为例[J].世界科学技术—中医药现代化,2022,24(5):1970-1980.
辛雪,黄大智.从专利分析角度比较中国和日本经典方剂的新药研究[J].中国新药杂志,2020,29(5):487-493.
林树元,徐玉,曹灵勇,等.经方医学理论源流发展述略[J].中华中医药杂志,2017,32(11):4873-4875.
邓中甲.方剂学[M].上海:上海科学技术出版社,2008:1-12.
罗莉.经方中成药制剂的问题研究[D].成都:成都中医药大学,2015.
江茹,沈爱玲.日本汉方药的专利保护政策及其借鉴意义[J].现代中药研究与实践,2012,26(2):76.
0
Views
19
下载量
1
CSCD
Publicity Resources
Related Articles
Related Author
Related Institution